Jazz Pharmaceuticals Raises FY2026 Sales Guidance from $4.600B-$4.750B to $4.775B-$4.850B vs $4.719B Est
Benzinga Newsdesk 6 hours ago
NewsGuidance
Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2026 sales outlook from $4.600 billion-$4.750 billion to $4.775 billion-$4.850 billion vs $4.719 billion estimate.
Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2026 sales outlook from $4.600 billion-$4.750 billion to $4.775 billion-$4.850 billion vs $4.719 billion estimate.